Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula(Chrono Therapeutics (United States)), William Mallet(Unknown), Henry B. Lowman, Kevin S. McDorman(Charles River Laboratories (Netherlands)), Jihong Yang, Chien C Lee, Suzanna Clark, Rayna Venook, Y. Gloria Meng, Susan D. Spencer, Eileen Duenas, Kelly M. Flagella(Unknown), Sylvia Weir, Douglas D. Leipold(Genesys (United States)), Yvonne Chen, Paul Polakis(Intarcia Therapeutics (United States)), Sunil Bhakta(Intarcia Therapeutics (United States)), Sarajane Ross, Jeffrey Gorrell, Mark S. Dennis(Denali Therapeutics (United States)), Yanmei Lu, Amy Kim, Siao Ping Tsai, Carl Ng, Richard H. Scheller(Howard Hughes Medical Institute), Michelle Simpson, Viswanatham Katta, Wai Lee Wong, Richard Vandlen(PDL BioPharma (United States)), Mark X. Sliwkowski(Molecular Oncology (United States)), Helga Raab
Cited by 1,353
Related Papers
Wnt signaling and cancer
|Genes & Development|2000|3.2k
SNAREs — engines for membrane fusion
|Nature Reviews Molecular Cell Biology|2006|2.6k
Syntaxin: A Synaptic Protein Implicated in Docking of Synaptic Vesicles at Presynaptic Active Zones
|Science|1992|1.3k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997